Services Agreement Addendum No. 2 between Phage Biotechnology Corporation and MPI Research, Inc. (December 31, 2004)
This addendum is an agreement between Phage Biotechnology Corporation and MPI Research, Inc. for a 4-week dermal toxicity study of recombinant human growth factor (FGF-1) in rats. The study is scheduled to start on December 29, 2004, with a final report expected by April 20, 2005. The total study price is $50,400, with payments due at specified milestones. The addendum is governed by the terms of a master agreement between the parties and outlines how any price modifications will be handled.
EXHIBIT 10.14(b)
[LETTERHEAD OF MPI RESEARCH]
SERVICES AGREEMENT ADDENDUM No. 2
Sponsor: Phage Biotechnology Corporation
Sponsor’s Representative: Jack Jacobs, Ph.D.
Date: December 31, 2004
Study Type: A 4-Week Dermal Toxicity Study of Recombinant Human Growth Factor (FGF-1) in Rats
Study Director: Robert Tawoda
Sponsor’s Study No.:
MPI Research Study No.: 1118-002
MPI Research Proposal No.: 04-082218
Study Schedule:
| Estimated Start Date: | December 29, 2004 | |||
| Estimated Date of Terminal Necropsy: | January 25, 2005 | |||
| Estimated Audited Draft Report Date: | April 20, 2005 |
Study Price: $50,400 Original
Payment Schedule:
| Animal Acquisition | $30,200 | |||
| 30 Days After Initial Billing | $15,200 | |||
| At Mailing of Audited Draft Report | $ 5,000 |
THE WORK DESCRIBED IN THIS PROTOCOL WILL BE DONE UNDER THE TERMS AND CONDITIONS OF THE MASTER AGREEMENT BETWEEN MPI RESEARCH AND (Enter Sponsor Here) DATED (Enter Date Here) AND THIS ADDENDUM NO. IS INCORPORATED INTO AND MADE A PART OF SAID MASTER AGREEMENT. MODIFICATIONS TO THE STUDY PRICE, MUTUALLY AGREED UPON IN WRITING BY THE PARTIES, THAT OCCUR DURING THE COURSE OF THE ABOVE DEFINED PAYMENT SCHEDULE WILL BE REFLECTED ON THE NEXT SCHEDULED INVOICE, UNLESS OTHERWISE NOTED.
| /S/ JACK JACOBS | /S/ ANDREJS DUMPIS | |||
| On behalf of (Enter Sponsor Here) | On behalf of MPI Research, Inc. | |||
| Date: 1/11/05 | Date: 1/5/05 | |||
